5,921 Labcorp Holdings Inc. $LH Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 14.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 35,533 shares of the medical research company’s stock after selling 5,921 shares during the period. Leeward Investments LLC MA’s holdings in Labcorp were worth $10,948,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its position in Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock valued at $607,241,000 after buying an additional 22,170 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Labcorp by 2.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock worth $355,569,000 after buying an additional 28,584 shares during the period. Royal Bank of Canada increased its position in shares of Labcorp by 19.4% during the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock valued at $218,901,000 after acquiring an additional 133,549 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in shares of Labcorp during the second quarter valued at about $168,222,000. Finally, Bessemer Group Inc. increased its position in shares of Labcorp by 47.3% during the first quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock valued at $154,493,000 after acquiring an additional 185,847 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Labcorp Price Performance

LH opened at $329.10 on Monday. The stock’s 50-day moving average price is $320.94 and its 200 day moving average price is $291.11. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $341.80. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The firm has a market cap of $26.69 billion, a price-to-earnings ratio of 27.22, a PEG ratio of 1.88 and a beta of 0.87.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. Labcorp’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business posted $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, sell-side analysts expect that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s dividend payout ratio is currently 23.82%.

Insider Transactions at Labcorp

In other news, Director Kerrii Anderson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the completion of the transaction, the director owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. This trade represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam Schechter sold 4,669 shares of Labcorp stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the transaction, the chief executive officer owned 102,565 shares of the company’s stock, valued at $32,858,749.05. This trade represents a 4.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,593 shares of company stock valued at $2,733,295. 0.84% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on LH shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $306.00 price target on shares of Labcorp in a research note on Friday, July 31st. Weiss Ratings raised shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday. UBS Group increased their price objective on shares of Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Barclays lifted their target price on shares of Labcorp from $320.00 to $330.00 and gave the company an “equal weight” rating in a report on Friday, September 11th. Finally, JPMorgan Chase & Co. boosted their target price on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $337.73.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.